Journal Banner

Supervised ART interruption to allow HCV therapy with DAAs in HIV/HCV co-infected subjects.

Introduction of direct-acting antivirals (DAAs) for chronic hepatitis C (HCV) has significantly improved sustained virologic response (SVR) for HCV-infected patients. However treatment of HCV for some HIV/HCV co-infected patients has been deferred due to drug interactions with concomitant antiretroviral medications. Here we report the experience of three subjects who had advanced liver fibrosis due to HCV who underwent supervised ART interruption to allow HCV therapy with DAAs.

Author(s): Angie Price, Chloe Gross, Elizabeth Akoth, Eleanor Wilson, Anu Osinusi, Shyamasundaran Kottilil